BRPI0908194B8 - Uso de uma anexina a5 recombinante, e stent de eluição de fármaco - Google Patents

Uso de uma anexina a5 recombinante, e stent de eluição de fármaco

Info

Publication number
BRPI0908194B8
BRPI0908194B8 BRPI0908194A BRPI0908194A BRPI0908194B8 BR PI0908194 B8 BRPI0908194 B8 BR PI0908194B8 BR PI0908194 A BRPI0908194 A BR PI0908194A BR PI0908194 A BRPI0908194 A BR PI0908194A BR PI0908194 B8 BRPI0908194 B8 BR PI0908194B8
Authority
BR
Brazil
Prior art keywords
drug
analogue
functional variant
eluting stent
stent
Prior art date
Application number
BRPI0908194A
Other languages
English (en)
Inventor
Pettersson Knut
Camber Ola
Frostegård Johan
Original Assignee
Athera Biotechnologies Ab
Medirista Ab
Annexin Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab, Medirista Ab, Annexin Pharmaceuticals Ab filed Critical Athera Biotechnologies Ab
Publication of BRPI0908194A2 publication Critical patent/BRPI0908194A2/pt
Publication of BRPI0908194B1 publication Critical patent/BRPI0908194B1/pt
Publication of BRPI0908194B8 publication Critical patent/BRPI0908194B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3625—Vascular tissue, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Materials Engineering (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

ANEXINA A5 OU UM ANÁLOGO OU VARIANTE FUNCIONAL DA MESMA, USO DOS MESMOS, COMPOSIÇÃO FARMACÊUTICA, STENT DE ELUIÇÃO DE FÁRMACO, E, MÉTODO PARA FABRICAR UM STENT. Um método para a profilaxia ou o tratamento de restenose que compreende administrar uma quantidade terapeuticamente eficaz de Anexina A5 ou um análogo ou variante funci-onal da mesma a um paciente em necessidade de tal tratamento. Um método para o tratamento de estenose em um paciente que compreende realizar uma intervenção para o tratamento de estenose em conjunção com a administração de uma quantidade terapeuti-camente eficaz de Anexia A5 ou um análogo ou variante funcional da mesma. Uma compo-sição farmacêutica que compreende uma quantidade terapeuticamente eficaz de Anexia A5 ou um análogo ou variante funcional da mesma para a profilaxia ou o tratamento de restenose. Um stent de eluição de fármaco, em que o fármaco é Anexia A5 ou um análogo ou variante funcional da mesma, e um método de fabricar um tal stent.
BRPI0908194A 2008-02-22 2009-02-20 Uso de uma anexina a5 recombinante, e stent de eluição de fármaco BRPI0908194B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3080308P 2008-02-22 2008-02-22
US61/030,803 2008-02-22
PCT/GB2009/000454 WO2009103977A1 (en) 2008-02-22 2009-02-20 Compounds and methods for the prevention or treatment of restenosis

Publications (3)

Publication Number Publication Date
BRPI0908194A2 BRPI0908194A2 (pt) 2016-07-05
BRPI0908194B1 BRPI0908194B1 (pt) 2022-01-04
BRPI0908194B8 true BRPI0908194B8 (pt) 2023-03-28

Family

ID=40723470

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908194A BRPI0908194B8 (pt) 2008-02-22 2009-02-20 Uso de uma anexina a5 recombinante, e stent de eluição de fármaco

Country Status (15)

Country Link
US (3) US9295716B2 (pt)
EP (2) EP3216457B1 (pt)
JP (4) JP2011512393A (pt)
KR (1) KR101692392B1 (pt)
CN (1) CN101969978A (pt)
AU (1) AU2009216543B2 (pt)
BR (1) BRPI0908194B8 (pt)
CA (1) CA2715859C (pt)
DK (2) DK3216457T3 (pt)
ES (2) ES2733902T3 (pt)
HU (2) HUE035034T2 (pt)
MX (1) MX2010009270A (pt)
PL (2) PL3216457T3 (pt)
TR (1) TR201909412T4 (pt)
WO (1) WO2009103977A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2349321B1 (en) * 2008-10-17 2020-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
US20110250208A1 (en) 2008-12-19 2011-10-13 Frostegaard Johan Oxidized Cardiolipin as a Novel Pro-Inflammatory Factor
WO2011160845A2 (en) 2010-06-24 2011-12-29 Medirista Biotechnologies Ab Oxidized phospholipids and lipoproteins, and antibodies thereto, as biomarkers of inflammatory conditions and methods of treatment
US20140037614A1 (en) * 2011-04-05 2014-02-06 Knut Pettersson Therapeutic and prophylactic methods, uses and compositions comprising anexin a5
GB201322777D0 (en) * 2013-12-20 2014-02-05 Algipharma As Use of alginate oligomers as blood anticoagulants
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
GB201702144D0 (en) * 2017-02-09 2017-03-29 Annexin Pharmaceuticals Ab Therapeutic compositions
CN111388152B (zh) * 2018-12-27 2021-12-03 元心科技(深圳)有限公司 药物洗脱器械及其制备方法
CN111494608A (zh) * 2020-05-08 2020-08-07 北京大学第三医院（北京大学第三临床医学院） 预防或治疗子痫前期及相关病症的药物及其应用
CN113317879B (zh) * 2021-05-28 2022-06-07 郑州大学第一附属医院 一种预测肝硬化患者tips术后支架再狭窄的试剂盒
US20240141001A1 (en) 2021-06-14 2024-05-02 Institut National de la Santé et de la Recherche Médicale Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
KR102823180B1 (ko) * 2022-09-08 2025-06-20 건국대학교 글로컬산학협력단 Annexin A5를 코팅하고 항원을 탑재한 나노입자 및 이의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545208A (en) * 1990-02-28 1996-08-13 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5122154A (en) * 1990-08-15 1992-06-16 Rhodes Valentine J Endovascular bypass graft
US6602281B1 (en) 1995-06-05 2003-08-05 Avantec Vascular Corporation Radially expansible vessel scaffold having beams and expansion joints
US5922020A (en) 1996-08-02 1999-07-13 Localmed, Inc. Tubular prosthesis having improved expansion and imaging characteristics
AU2001237805A1 (en) * 2000-02-08 2001-08-20 Acspurt B.V. Material and method for immobilization of bioactive species
US6602282B1 (en) 2000-05-04 2003-08-05 Avantec Vascular Corporation Flexible stent structure
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US6962903B2 (en) 2001-02-21 2005-11-08 Alavita, Inc. Modified annexin proteins and methods for preventing thrombosis
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
CN1659180B (zh) * 2002-06-06 2010-06-02 温子坚 新型的重组抗凝血蛋白
CA2508214A1 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
US20050037052A1 (en) * 2003-08-13 2005-02-17 Medtronic Vascular, Inc. Stent coating with gradient porosity
US20060083772A1 (en) 2004-04-06 2006-04-20 Dewitt David M Coating compositions for bioactive agents
ES2356364T3 (es) * 2004-04-15 2011-04-07 Athera Biotechnologies Ab Anexina v para prevenir la ruptura de la placa.
CA2708956C (en) * 2007-12-18 2018-07-17 Athera Biotechnologies Ab Use of annexin a5 for the treatment of vascular disease
CN103262479B (zh) * 2010-12-17 2016-08-10 日本电气株式会社 通信系统、节点、分组转发方法

Also Published As

Publication number Publication date
BRPI0908194B1 (pt) 2022-01-04
JP6889193B2 (ja) 2021-06-18
CA2715859A1 (en) 2009-08-27
JP2015007074A (ja) 2015-01-15
KR20100122501A (ko) 2010-11-22
TR201909412T4 (tr) 2019-07-22
JP5964369B2 (ja) 2016-08-03
BRPI0908194A2 (pt) 2016-07-05
US9295716B2 (en) 2016-03-29
AU2009216543B2 (en) 2014-07-24
KR101692392B1 (ko) 2017-01-03
JP2011512393A (ja) 2011-04-21
WO2009103977A1 (en) 2009-08-27
US9901614B2 (en) 2018-02-27
CN101969978A (zh) 2011-02-09
AU2009216543A1 (en) 2009-08-27
PL2254589T3 (pl) 2017-11-30
CA2715859C (en) 2021-07-20
EP3216457A1 (en) 2017-09-13
ES2733902T3 (es) 2019-12-03
HUE035034T2 (en) 2018-05-02
ES2630013T3 (es) 2017-08-17
US20100331970A1 (en) 2010-12-30
HUE044621T2 (hu) 2019-11-28
PL3216457T3 (pl) 2019-09-30
JP2016175946A (ja) 2016-10-06
DK3216457T3 (da) 2019-07-15
DK2254589T3 (en) 2017-07-10
EP2254589B1 (en) 2017-04-05
EP3216457B1 (en) 2019-04-10
US20160250284A1 (en) 2016-09-01
EP2254589A1 (en) 2010-12-01
MX2010009270A (es) 2010-09-24
US20180140668A1 (en) 2018-05-24
JP2019081805A (ja) 2019-05-30

Similar Documents

Publication Publication Date Title
BRPI0908194B8 (pt) Uso de uma anexina a5 recombinante, e stent de eluição de fármaco
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
CR9989A (es) Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MX2016015516A (es) Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada.
BR112012011298A2 (pt) métodos de tratar ou previnir trombose de stent
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
BR112012006010A2 (pt) composto de glicina
PL1986669T3 (pl) Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
BRPI0823082B8 (pt) composições de derivados de sesquiterpeno para prevenir ou tratar hiperlipidemia, fígado gordo, diabetes ou obesidade
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
MX2011011656A (es) Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento.
UY34359A (es) ?tratamiento de esclerosis múltiple con combinación de laquinimod e interferón-beta?.
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/02/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25A Requested transfer of rights approved

Owner name: MEDIRISTA AB (SE)

B25A Requested transfer of rights approved

Owner name: ANNEXIN PHARMACEUTICALS AB (SE)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.